Document:

EX-10.7

 Exhibit 10.7 

CHINA AND SOUTH KOREA IP PURCHASE AGREEMENT 

This CHINA AND SOUTH KOREA IP PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 12th day of June, 2017
(“Effective Date”), by and between Dermavant Sciences GmbH, a Switzerland limited liability company with an address of c/o Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland
(“Seller”), and Roivant Sciences GmbH, a Switzerland limited liability company with an address of c/o Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland (“Buyer”). Each
of the Seller and the Buyer are referred to in this Agreement as a “party” and together as the “parties”. 
 WHEREAS,
the Buyer is an affiliate of the Seller, and both the Buyer and the Seller are wholly-owned, indirect subsidiaries of Roivant Sciences Ltd.; 

WHEREAS, the Seller is the owner of all right, title, claim and interest in the Assigned Assets (defined below); 

WHEREAS, as part of an internal reorganization, Seller as the owner of Assigned Assets, desires to sell, assign, transfer, convey, grant and
deliver to Buyer, all of Seller’s right, title, claim and interest in and to and Buyer desires and is willing to accept from Seller, the Assigned Assets (defined below) “as-is”; and 

NOW THEREFORE, in consideration of the mutual covenants set forth herein, the parties hereby represent, covenant and agree as follows: 

1. Sale of Assigned Assets. Seller hereby sells, transfers, assigns, conveys, grants and delivers to Buyer, “as-is”, “where-is” and with all faults, effective as of the Effective Date, to have and to hold forever, all of Seller’s right, title, claim and
interest, that exists today or may exist in the future, in and to (i) any and all intellectual property rights, whether existing as of the Effective Date or hereafter, solely in the countries of China, including Hong Kong, Macau, Taiwan and all
other territories of China (collectively, “China”) and the Republic of Korea and all territories thereof (“South Korea”), including, but not limited to, inventions (whether patentable or not), patents, patent applications,
trademarks, trade names, service names, domain names, trade dress, copyrights, works of authorship, trade secrets, know-how, data, intellectual property license agreements and any other proprietary information
(including all rights to sue and recover and retain damages, costs and attorneys’ fees for past, present and future infringement and any other rights relating to any of the foregoing), including those set forth in Schedule I, and further
including any moral rights and/or goodwill and activities associated with any of the foregoing solely in China and South Korea; and (ii) all of the properties, assets, and agreements identified on Schedule I hereto solely as it relates
to any rights or obligations in China and South Korea (collectively (i) and (ii), the “Assigned Assets”). 
 a. The
Assigned Assets shall be held and enjoyed by Buyer, its successors and assigns from and after the date of such assignment as fully and entirely as the same would have been held and enjoyed by Seller had such assignment not been made.

 2. As of the Effective Date, the Buyer hereby receives and accepts the assignment, transfer
and conveyance of the rights and properties hereby assigned, transferred and conveyed to it herein from Seller. 
 3. Assignment of
Agreements and Rights. Anything in this Agreement to the contrary notwithstanding, this Agreement shall not constitute an agreement to assign, or an assignment of, any Assigned Asset or any claim or right or any benefit arising thereunder or
resulting therefrom if an attempted assignment thereof would constitute a breach or other contravention thereof or in any way adversely affect the rights of Seller or Buyer thereunder. Seller and Buyer will use their best efforts to obtain the
consent of the other parties to any such Assigned Asset or claim or right or any benefit arising thereunder for the assignment thereof to Buyer. Until the time any such consent is received, Seller shall be deemed to have assigned to Buyer hereby the
economic benefit of Seller from and after the date hereof under any such Assigned Asset and shall hold any such Assigned Asset in trust for Buyer, and Buyer shall have been deemed to have assumed the obligations of Seller from and after the
Effective Date under any such Assigned Asset. If any such consent is not obtained, or if an attempted assignment thereof would be ineffective or would adversely affect the rights of Seller thereunder so that Buyer would not in fact receive all such
rights, the parties will cooperate in a mutually agreeable arrangement under which Buyer would obtain the benefits and assume the obligations thereunder in accordance with this Agreement, including subcontracting,
sub-licensing, or subleasing to Buyer, or under which Seller would enforce for the benefit of Buyer, with Buyer assuming Seller’s obligations, any and all rights of Seller against a third party thereto.
Seller will promptly pay to Buyer all monies received by Seller pursuant to any Assigned Asset or any claim or right or any benefit arising thereunder from and after the Effective Date. 

4. Purchase Price: The purchase price for the Assigned Assets shall be the fair market value agreed to be Five Hundred Thousand U.S.
Dollars ($500,000.00 USD) plus applicable Swiss VAT of 8%. The Parties shall be entitled to amend this agreement in order to determine another purchase price representing such fair market value, e.g. on advice by Cabrillo Advisors. For the avoidance
of doubt, as of the Effective Date the Buyer hereby undertakes, assumes and promises to pay and to perform, satisfy and discharge any future liabilities, duties, responsibilities and obligations of Seller arising out of the Assigned Assets. 

5. Power of Attorney. Without limiting the above, Seller does hereby constitute and appoint Buyer, its successors and assigns, as
Seller’s true and lawful attorney-in-fact, with full power of substitution and resubstitution, for it and in its name, place and stead, but on behalf of and for the
benefit of Buyer, its successors and assigns: 
 a. to demand and receive from time to time any and all Assigned Assets conveyed, transferred
and assigned to Buyer pursuant to this Agreement, and to give receipts and releases for and in respect of the same and any part thereof; 

b. from time to time to institute and prosecute in its name or otherwise, but at the direction and expense and for the benefit of Buyer and its
successors and assigns, any and all proceedings at law, in equity or otherwise, which Buyer, its successors or assigns may deem proper in order to collect, assert or enforce any claim, right or title of any kind in and to the Assigned Assets
transferred and assigned to Buyer pursuant to this Agreement, and to defend and compromise any and all actions, suits and proceedings in respect of any of said property, assets and business and to do any and all such acts and things in relation
thereto as Buyer, its successors or assigns shall deem advisable; and 

  
 -2- 

 c. to do all other things legally permissible or reasonably deemed by Buyer to be required
to recover the assets conveyed by Seller, hereby declaring that the appointment hereby made and the powers hereby granted are coupled with an interest and are and shall be irrevocable by Seller in any manner or for any reason. 

6. Representations and Warranties. Each of Seller and Buyer, as applicable, represents on behalf of itself to the other as follows: 

a. each party (i) is a limited liability company, with restricted liability, duly organized, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or organization, and (ii) is qualified to do business and is in good standing as a foreign corporation or organization in each jurisdiction in which the conduct of its business or the ownership
of its properties requires such qualification and failure to have such qualification would prevent such party from performing its obligations under this Agreement; 

b. each party has the requisite power and authority and has taken all action necessary in order to execute, deliver and perform this Agreement
and to consummate the transactions contemplated hereby; 
 c. this Agreement has been duly executed and delivered by it and constitutes a
valid and binding agreement of it enforceable in accordance with the terms hereof, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other similar laws relating to the enforcement of creditors’ rights
generally and by general principles of equity; 
 d. the execution, delivery and performance of this Agreement by each party does not:
(i) violate any law, regulation, order, writ, decree, determination or award of any court, governmental or administrative or other agency having jurisdiction over such party, or (ii) conflict with, or constitute a default under, any
agreement, instrument or understanding, or court or administrative order, oral or written, to which such party is a party or by which such party is bound; and 

e. The Seller represents and warrants to the Buyer that to the knowledge of the Seller, the Seller is the legal and beneficial owner of, and
has good and marketable title to all of the Assigned Assets, free and clear of all liens, claims, charges and encumbrances. 
 The representations and
warranties set out in this Agreement, and all covenants of the parties set out in this Agreement will survive the Closing and, notwithstanding such Closing, will continue in full force and effect for the benefit of the Buyer or the Seller, as the
case may be, in accordance with the terms thereof. 

  
 -3- 

 7. Further Assurances. Seller will, from time to time, execute and deliver, or cause
to be executed and delivered, such additional instruments, notices, releases, certificates, powers of attorney, assurances, bills of sale, and other documents and do all such further acts, assignments, transfers and other things, as may reasonably
be requested by Buyer in order to more completely assign and transfer the Assigned Assets, and for the effective confirmation, consummation and particularization of this Agreement, including but not limited to updating registrations in the
respective jurisdictions. 
 8. Costs and Expenses. Each of the parties hereto shall pay its own expenses and costs incurred or to be
incurred in negotiating, closing and executing the transactions contemplated by this Agreement. The Buyer shall be responsible for any applicable taxes payable, if any, as a result of the transfer of the Assigned Assets except for Swiss VAT that is
payable by the Seller. 
 9. Severability. If any provision of this Agreement of the application thereof to any person or circumstance
is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof, or the application of such provision to persons or circumstances or in jurisdictions other than those as to which it has been
held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner
adverse to any party. 
 10. Entire Agreement. This Agreement constitutes the final agreement between the parties with respect to the
subject matter contained herein, and is the complete and exclusive statement of the parties’ agreement on the matters contained herein. All prior and contemporaneous negotiations and agreements between the parties with respect to the matters
contained herein are superseded by this Agreement. 
 11. Amendments and Waiver. No modification, waiver or amendment of this
Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof unless otherwise expressly provided. 

12. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the
parties hereto. This Agreement does not confer rights on any person other than the parties to this agreement and their successors and Buyers. 

13. Governing Law. This Agreement and all matters relating thereto and arising therefrom shall be governed by, administered under and
construed in accordance with the laws of Switzerland, without reference to provisions of conflicts of laws, and the courts of Basel/Switzerland shall have exclusive jurisdiction with respect thereto. 

14. Counterparts. This Agreement may be executed in two or more counterparts and by facsimile signature, each of which shall be deemed
an original, but all of such counterparts together shall constitute one and the same instrument. The signatures of both parties need not appear on the same document. The delivery of signed counterparts by facsimile or email transmission that
includes a copy of a sending party’s signature is as effective as signing and delivering the counterpart in person. 

  
 -4- 

 15. Successors and Assigns. This Agreement shall be binding on and inure to the
benefit of the parties hereto, their successors in interest and assigns. 
 [signature page follows] 

  
 -5- 

 IN WITNESS WHEREOF, this Agreement has been duly executed by the undersigned as of the date
set forth above. 
  

			
	The Seller: Dermavant Sciences GmbH
	(Seller)	 	
		
	By:	 	 /s/ Marianne Romeo Dinsmore

	Name:	 	Marianne Romeo Dinsmore
	Title:	 	Managing Director
	Date:	 	12 June 2017
	Place:	 	Bermuda

  

			
	WITNESS 1:
		
	By:	 	 /s/ Melissa Butler

	Name:	 	Melissa Butler
	
	WITNESS 2:
		
	By:	 	 /s/ Christie Meacham

	Name:	 	Christie Meacham

 ATTESTATION 

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine
signature of Ms. Marianne Romeo Dinsmore, citzen of the United States of America, residing in Hamilton, Bermuda; acting for Dermavant Sciences GmbH, in Basel, Switzerland, as Managing Director, with single signature.

 The authenticity of the signature was established by means of comparison. 

BASEL, Switzerland, this 26th (twenty-sixth) day of June 2017 (two thousand and seventeen) 

M. Staehelin, Nob 
 Leg.Prot.Nr. 1286/2017 

 
			
	The Buyer: Roivant Sciences GmbH
		
	By:	 	 /s/ Ruben Masar

	Name:	 	Ruben Masar
	Title:	 	Secretary
	Date:	 	                        
	Place:	 	Basel, Switzerland

  

			
	WITNESS 1:
		
	By:	 	 /s/ Silvia Plattner

	Name:	 	Silvia Plattner
	
	WITNESS 2:
		
	By:	 	 /s/ Sebastian Fluckiger

	Name:	 	Sebastian Fluckiger

 ATTESTATION 

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signature attached heretofore is the genuine
signature of Mr. Ruben Masar, citizen of Basel, Switzerland, residing in Basel, Switzerland; acting for Roivant Sciences GmbH, in Basel, Switzerland, as authorized signatory, with single signature. 

The authenticity of the signature was established by means of comparison. 

BASEL, Switzerland, this 26th (twenty-sixth) day of June 2017 (two thousand and seventeen) 

M. Staehelin, Nob 
 Leg.Prot.Nr. 1287/2017 

 SCHEDULE I 

ASSIGNED ASSETS 

Patents: 
 The right to file one or more patent
applications in China and South Korea that claim priority to any of the following: 
  

													
	 Case

Number
	 	 Country
	 	 Application

Number
	 	 Filing Date
	 	 Patent

Number
	 	 Issue Date
	 	 Status

	143989.00900	 	US	 	62/347,006	 	06/07/2016	 		 		 	Pending
	143989.00910	 	US	 	62/449,753	 	01/24/2017	 		 		 	Pending
	143989.00920	 	US	 	62/488,495	 	04/21/2017	 		 		 	Pending

 Agreements: 
  

	 	•	 	 License, Development and Commercialization Agreement between Dermavant Sciences GmbH (as successor in interest to
Dermavant Sciences Ltd., who is successor in interest to Roivant Sciences Ltd., who is successor in interest to Roivant Hepatology Ltd.) and Vertex Pharmaceuticals Incorporated dated December 30, 2014 solely as it relates to any rights or
obligations in China and South Korea 

  

	 	•	 	 License Agreement between Dermavant Sciences GmbH (as successor in interest to Dermavant Sciences Ltd., who is
successor in interest to Roivant Sciences Ltd.) and Eisai Co., Ltd. dated November 19, 2015 solely as it relates to any rights or obligations in China and South Korea 

 

	 	•	 	 License Agreement between Portola Pharmaceuticals, Inc. and Dermavant Sciences GmbH dated December 16, 2016
solely as it relates to any rights or obligations in China and South KoreaEX-10.8

 Exhibit 10.8 

CONFIDENTIAL 
 Execution Copy 

ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment and Assumption Agreement”) is made and entered into as of
December 17, 2018 (the Effective Date”), by and between Dermavant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051,
Switzerland (“DSG”) and Roivant Sciences GmbH, a company organized and existing pursuant to the laws of Switzerland having a principal place of business at Viaduktstrasse 8, Basel 4051, Switzerland (“RSG”). 

A. WHEREAS, RSG entered into a License Agreement with AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its
registered office at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”) effective as of
September 19, 2017 (the “AZ Agreement”), pursuant to which RSG received an exclusive license from AstraZeneca to research, develop, manufacture and commercialize certain products for all diagnostic, prophylactic and therapeutic
uses in humans and animals; 
 B. WHEREAS, RSG and Roivant China Holdings Ltd. (formerly known as Sinovant Sciences Ltd., a Bermuda exempted
limited company) (“SSL”), entered into that certain China and South Korea IP Purchase Agreement, dated February 14, 2018 (the “Sinovant Agreement”), pursuant to which RSG assigned all of its rights under the AZ
Agreement to SSL relating to China, Hong Kong, Macau and Taiwan (“Greater China”) and the Republic of Korea and all territories thereof (“South Korea”, and together with Greater China, the “Reserved
Territory”), as more specifically set forth therein., as more specifically set forth therein. 
 C. WHEREAS, SSL and its
subsidiary, Sinovant Sciences HK Limited (“SinoHK”), entered that certain Intellectual Property License Agreement, dated March 16, 2018, pursuant to which SSL sublicensed to SinoHK, inter alia, its intellectual property rights
under the Sinovant Agreement in The Reserved Territory; 
 D. WHEREAS, RSG desires to assign and transfer to DSG all of RSG’s rights
and obligation under the AZ Agreement, as set forth below (which, for clarity, excludes the rights transferred to SSL pursuant to the Sinovant Agreement), and DSG desires to accept such assignment and transfer. 

NOW, THEREFORE, for good and valuable consideration, the receipt, adequacy and legal sufficiency of which are hereby acknowledged, the parties
hereto hereby agree as follows: 
 1. Defined Terms. Capitalized terms used but not otherwise defined in this Assignment and
Assumption Agreement shall have the meanings given to such terms in the AZ Agreement. 

  
 - 1 - 

 2. Assignment; Reversion. 

(a) Initial Assignment. RSG hereby grants, conveys, transfers and assigns to DSG and its successors and assigns, all of the rights,
title and interests of RSG in and to (a) the AZ Agreement (including pursuant to the Transition Plan thereunder), excluding as it relates to any rights, title or interests that have, as of the Effective Date, been assigned, licensed,
sublicensed by or on behalf of RSG to any Affiliate of RSG or any Third Party, whether directly or indirectly, to develop and commercialize any Licensed Product in the Reserved Territory, (b) any and all Licensee Patents, Licensee Know-How and any Improvements and all other intellectual property rights of RSG under the AZ Agreement, excluding any intellectual property rights that have, as of the Effective Date, been assigned, licensed,
sublicensed by or on behalf of RSG to any Affiliate of RSG or any Third Party, whether directly or indirectly, to develop and commercialize any Licensed Product in the Reserved Territory and (c) any and all Regulatory Documentation for Licensed
Compounds and Licensed Products in the Field in the Territory, excluding any Regulatory Documentation that has, as of the Effective Date, been assigned, licensed, sublicensed by or on behalf of RSG to any Affiliate or Third Party, whether directly
or indirectly, to develop and commercialize any Licensed Product in the Reserved Territory (collectively, the “Assigned Assets”). 

(b) Reversion; Additional Assignments to DSG. Without limiting Section 2(a), if RSG has granted to an Affiliate of RSG or any Third
Party some or all of its rights in any country(ies) or administrative jurisdiction(s) in the Reserved Territory under the AZ Agreement as of the Effective Date, and the agreement with such Affiliate or such Third Party is modified or terminated
following the Effective Date in a manner that causes a reversion of such rights under the AZ Agreement in such country(ies) or administrative jurisdiction(s) to RSG, then, RSG may exploit such rights in any such reverted country(ies) or
administrative jurisdiction(s) on behalf of itself or may grant, transfer or otherwise convey such rights to an Affiliate of RSG, in either case, without further obligation to DSG hereunder. Notwithstanding the foregoing, upon any such reversion of
rights to RSG, unless otherwise agreed in writing, RSG shall not grant, transfer or otherwise convey any of the reverted rights under the AZ Agreement for the exploitation of Licensed Products or Licensed Compounds in the Reserved Territory to any
Third Party unless otherwise required by the Section 2.4 of the AZ Agreement. If RSG elects not to exploit such reverted rights under the AZ Agreement itself or through a grant, transfer or conveyance of rights to an Affiliate of RSG, then RSG
shall and hereby does grant, convey, transfer and assign to DSG and its successors and assigns, all of the rights, title and interests of RSG in and to (i) the AZ Agreement, (ii) Licensee Patents, Licensee
Know-How and any Improvements and (iii) any Regulatory Documentation for Licensed Compounds and Licensed Products in such reverted country or administrative jurisdiction in the Reserved Territory, in each
case of (i)-(iii) to the extent reasonably possible without violating applicable law or any contractual agreement with any Third Party. Following such assignment, the ‘Assigned Assets’ shall automatically include those assets described in
the foregoing sentence (i)-(iii), which, unless otherwise agreed will automatically be sublicensed by DSG back to RSG for use outside of dermatology pursuant to that certain Sublicense Agreement by and between DSG and RSG, dated as of the date
hereof (the “Sublicense Agreement”). RSG shall promptly notify DSG of any termination of modification of any agreement with any Affiliate or Third Party involving the rights under the AZ Agreement in some or all of the Retained
Territory and the Parties shall, on DSG’s request, meet in good faith to discuss such additional assignment of rights and any appropriate agreements or amendments to existing agreements required in connection with the same. 

  
 - 2 - 

 3. Assumption of Liabilities. DSG does hereby assume and agree to pay, perform, honor
and discharge, as and when due, any obligations and liabilities that may arise under the AZ Agreement from the date hereof to the extent transferred to DSG under Section 2 above (the “Assumed Liabilities”). 

4. Consideration; Payment. Concurrently with the execution of this Assignment and Assumption Agreement, DSG shall pay to RSG (to an
account specified by RSG) an amount equal to two million U.S. dollars ($2,000,000), as consideration for the fair market value, as determined by an independent third party, of the assignment of the Assigned Assets and assumption of the Assumed
Liabilities. 
 5. Indemnification. Subject to RSG’s obligation to indemnify DSG pursuant to Section 6.2(a) of the
Sublicense Agreement, DSG shall indemnify, defend and hold RSG harmless from and against all liabilities, damages, expenses, losses, including reasonable legal expenses and attorneys’ fees, and any other expenses of any nature, resulting from
(a) DSG’s exercise of rights and performance or non-performance of its duties or obligations under the AZ Agreement to the extent assumed under this Agreement and/or (b) any other AstraZeneca
demand, claim, action, proceeding or liability after the date hereof (whether criminal or civil, in contract, tort or otherwise) against RSG arising or resulting from, or initiated under, the AZ Agreement (whether in reliance on joint and several
liability described in Section 10.3 of the AZ Agreement or otherwise), except to the extent related to (i) any rights or obligations under the AZ Agreement that are sublicensed by DSG back to RSG pursuant to the Sublicense Agreement or
(ii) the Reserved Territory or any of the rights or obligations under the AZ Agreement that were transferred pursuant to the Sinovant Agreement. 

6. Reversion Right. In the event that (a) DSG ceases all Development of Licensed Compounds and Licensed Products in the Field in
the Territory (or the funding thereof) with no plans to resume such Development (it being understood that the level of effort directed to such Development may change over time and may include reasonable periods where Development is temporarily de-prioritized or otherwise temporarily suspended), or (b) DSG notifies RSG in writing of its intention to proceed in the manner set forth in clause (a), then, RSG may elect to have all or part of the rights,
title and interests granted to DSG pursuant to Section 2 of this Assignment and Assumption Agreement, together with any or all of the Licensee Patents and Licensee Know-How, Improvements, Regulatory
Documentation, any licenses covering Third Party Patent Rights, and agreements with subcontractors for, and any or all other property or assets primarily relating to, the Licensed Compounds and Licensed Products in the Field in the Territory that
DSG Controls as of such time, assigned to RSG and its successors and assigns and DSG shall complete such assignment within thirty (30) days of DSG’s receipt of written notice of such election from RSG. Concurrently with the assignment, RSG
shall pay DSG (to an account specified by DSG) an amount intended to account for the fair market value of the transfer of such rights, as determined by an independent third party. If RSG elects to obtain such assignments, and solely to the extent
permissible under the AZ Agreement, on DSG’s request, RSG and DSG shall work in good faith to ensure that DSG is provided with the benefit of any of the property and assets assigned to RSG under this Section 6 (whether through non-exclusive licenses or otherwise) to the extent necessary or reasonably useful for the research, development and commercialization of DSG’s or its Affiliates’ products (other than the Licensed Products
and 

  
 - 3 - 

 Licensed Compounds). To the extent that RSG elects not to have assigned any of the foregoing items, DSG
shall terminate, cancel, wind-down or otherwise cease to support such retained items after assignment, unless the retention of such property or assets is (i) not prohibited or inconsistent with the AZ Agreement, and (ii) necessary or
reasonably useful for the research, development and commercialization of DSG’s or its Affiliates’ products (other than the Licensed Products or the Licensed Compounds). For the avoidance of doubt, the indemnification obligations set forth
in Section 5 of this Assignment and Assumption Agreement shall continue in full force and effect in respect of all indemnifiable losses that arose prior to such assignment. 

7. Successors and Assigns. This Assignment and Assumption Agreement shall bind and inure to the benefit of the respective successors and
assigns of DSG and RSG. 
 8. Governing Law. This Assignment and Assumption Agreement shall be governed by and construed in accordance
with the laws of the State of New York, without regard to conflict of laws principles. 
 9. No Third Party Rights. Nothing express or
implied in this Assignment and Assumption Agreement is intended or shall be construed to confer on any person other than DSG and RSG any rights under this Assignment and Assumption Agreement. 

10. Further Assurances. Each party hereto, upon the request of the other party hereto, whether before or after the Effective Date and
without further consideration, will do, execute, acknowledge, and deliver or cause to be done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney, instruments and
assurances as may be reasonably necessary to effect complete consummation of the transactions contemplated by this Assignment and Assumption Agreement, and to do all such other acts, as may be necessary or appropriate in order to carry out the
purposes and intent of this Assignment and Assumption Agreement. The parties hereto agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order
to consummate or implement expeditiously the transactions contemplated by this Assignment and Assumption Agreement. 
 11. Costs and
Expenses. Each of the parties hereto shall pay its own costs and expenses incurred or to be incurred in negotiating, closing and executing all transactions contemplated by this Assignment and Assumption Agreement. 

12. Counterparts. This Assignment and Assumption Agreement may be executed in any number of counterparts, each of which when so executed
and delivered shall be deemed an original, and such counterparts together shall constitute one instrument. 
 13. Amendments and
Waivers. The provisions of this Assignment and Assumption Agreement may be amended or waived only by an instrument in writing signed by DSG and RSG. Any waiver of any term or condition of this Assignment and Assumption Agreement or any breach
hereof shall not operate as a waiver of any other such term, condition or breach, and no failure to enforce any provision hereof shall operate as a waiver of such provision or of any other provision hereof. 

  
 - 4 - 

 14. Headings. The headings are for convenience only and will not control or affect
the meaning or construction of the provisions of this Assignment and Assumption Agreement. 
 [Signature Page Follows.] 

  
 - 5 - 

 IN WITNESS WHEREOF, the undersigned have caused this Assignment and Assumption Agreement to
be duly executed and delivered as of the date first above written. 
  

			
	ROIVANT SCIENCES GMBH
		
	By:	 	 /s/ Sascha Bucher

	Name:	 	Sascha Bucher
	Its:	 	 Roivant Sciences GmbH
 Sascha Bucher

VP, Head of Global Transactions

	
	DERMAVANT SCIENCES GMBH
		
	By:	 	 /s/ Ruben Masar

	Name:	 	Ruben Masar
	Its:	 	Secretary of the Board

 [Signature Page to Assignment and Assumption Agreement for
RVT-503]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]